Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.69 CAD | -1.82% |
|
+16.96% | -0.37% |
06-26 | Nervgen Pharma Initiated at Market Perform, $3 Price Target at Raymond James | MT |
06-25 | NervGen Pharma to Advance New Drug Candidate into Preclinical Proof-of-Concept Stage | MT |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.37% | 138M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- NGEN Stock
- News NervGen Pharma Corp.
- NervGen Pharma Corp. Announces Appointment of Amy Franke as Vice President, Clinical Operations